Novavax, Inc. Stock Nasdaq
Equities
US6700021040
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 987M | Sales 2025 * | 552M | Capitalization | 2.11B |
---|---|---|---|---|---|
Net income 2024 * | 68M | Net income 2025 * | -98M | EV / Sales 2024 * | 1.29 x |
Net cash position 2024 * | 837M | Net cash position 2025 * | 704M | EV / Sales 2025 * | 2.55 x |
P/E ratio 2024 * |
35.6
x | P/E ratio 2025 * |
-35.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.14% |
Latest transcript on Novavax, Inc.
Managers | Title | Age | Since |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |